文献速递乳腺癌

FALCON III期试验:氟维司群500mg与阿那曲唑治疗HR+晚期乳腺癌的健康相关生活质量分析

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.
PubMed 文献 · Eur J Cancer · 2018-03-22

FALCON III期随机试验纳入462例内分泌治疗初治的HR+局部晚期或转移性乳腺癌绝经后女性,随机接受氟维司群500mg或阿那曲唑1mg治疗。FACT-B问卷评估显示,两组TOI和FACT-B总分自基线平均变化基本稳定且组间相似,约三分之一患者TOI和FACT-B总分较基线改善。

要点

  • 氟维司群与阿那曲唑治疗期间HRQoL总体维持且组间相似。
  • 约三分之一患者TOI(≥+6分)和FACT-B总分(≥+8分)较基线改善。
  • FACT-B依从率总体范围为60.0%至97.4%。

核心结论

  • 氟维司群500mg与阿那曲唑1mg治疗期间,TOI和FACT-B总分自基线平均变化均维持稳定,两组相似。
  • 两组达到TOI和FACT-B总分改善的患者比例相似。

研究设计与样本

  • FALCON为III期随机试验(NCT01602380),纳入内分泌治疗初治的HR+局部晚期或转移性乳腺癌绝经后女性。
  • 患者按1:1随机接受氟维司群500mg(第0、14、28天,之后每28天)或阿那曲唑1mg(每日)直至疾病进展或停药。
  • 共462例患者随机(氟维司群n=230;阿那曲唑n=232),采用FACT-B问卷在随机时及治疗期间每12周评估HRQoL。

主要发现

  • TOI和FACT-B总分自基线平均变化在治疗至第132周期间大致稳定(约±3分),两组相似。
  • FACT-B各子量表HRQoL也维持稳定。
  • 治疗至第120周和第132周期间,氟维司群组TOI改善(≥+6分)比例范围为26.4-45.0%,FACT-B总分改善(≥+8分)比例范围为22.4-35.8%。
  • 阿那曲唑组TOI改善比例范围为18.6-32.9%,FACT-B总分改善比例范围为22.7-37.9%。

关键数值与推荐

  • FACT-B依从率总体范围为60.0%至97.4%。
  • TOI改善定义为较基线≥+6分,FACT-B总分改善定义为较基线≥+8分。

临床怎么用

  • 对于内分泌治疗初治的HR+局部晚期或转移性乳腺癌绝经后患者,氟维司群与阿那曲唑均可维持HRQoL。
  • 临床选择内分泌治疗时,HRQoL维持情况在两种药物间无实质差异。

局限性

  • FACT-B依从率总体范围为60.0%至97.4%,并非全部患者均有HRQoL数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (LA/MBC). Furthermore, overall health-related quality of life (HRQoL) was maintained and comparable for fulvestrant and anastrozole. Here, we present additional analyses of patient-reported HRQoL outcomes from FALCON. METHODS: Women with endocrine therapy-naïve HR+ LA/MBC were randomised 1:1 to fulvestrant (days 0, 14, 28, then every 28 d) or anastrozole (daily) until disease progression or discontinuation. HRQoL was assessed by FACT-B questionnaire (TOI and FACT-B total score) at randomisation and every 12 weeks during treatment. HRQoL data post-treatment (with or without progression) were also collected. RESULTS: In total, 462 patients were randomised (fulvestrant, n = 230; anastrozole, n = 232). Compliance to FACT-B overall ranged from 60.0 to 97.4%. Mean change from baseline in TOI and FACT-B total score remained broadly stable (approximately ± 3 points to week 132) and was similar between arms during treatment. HRQoL was also maintained in FACT-B subscales. Approximately one-third of patients had improved TOI (≥+6 points) and FACT-B (≥+8 points) total scores from baseline up to week 120 and 132, respectively, of treatment with fulvestrant (ranges 26.4-45.0% and 22.4-35.8%, respectively) and anastrozole (ranges 18.6-32.9%, and 22.7-37.9%, respectively). CONCLUSIONS: Mean change from baseline in TOI and FACT-B total score was maintained for fulvestrant and anastrozole; similar proportions of patients in both arms had improved TOI and FACT-B total scores. CLINICALTRIALS. GOV IDENTIFIER: NCT01602380.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Robertson JFR, Cheung KL, Noguchi S, et al. Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. Eur J Cancer. 2018. PMID: 29574365. doi:10.1016/j.ejca.2018.02.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。